-
Drugs
-
Drug Nomenclature Monographs
| Drug Nomenclature Monographs |
Monograph Number |
|
|
|
| Drug Classification | C-DRG-00101 |
| Dosage Form | C-DRG-00201 |
| Route of Administration | C-DRG-00301 |
| Ingredient Name | C-DRG-00401 |
| Proprietary Name | C-DRG-00402 |
| Animal Common Names | C-DRG-00403 |
| Animal Cell Tissue Fluid Biomolecule | C-DRG-00404 |
| Biotechnology Origin | C-DRG-00405 |
| Potency | C-DRG-00501 |
| Indications | C-DRG-00601 |
| Therapeutic Equivalence Code | C-DRG-00701 |
| Phase 4 Commitment Category | C-DRG-00901 |
| Phase 4 Fulfillment Category | C-DRG-00902 |
| Pediatric use Supplement Rule | C-DRG-00903 |
| Pediatric Use Supplement Clinical Efficacy Trials Category | C-DRG-00904 |
| Pediatric Use Supplement PK/PD Category | C-DRG-00905 |
| Pediatric Use Supplement Safety/Adverse Reaction Category | C-DRG-00906 |
| Package Type | C-DRG-00907 |
| Pediatric Exclusivity Study Type | C-DRG-00908 |
| Pediatric Exclusivity Study Age Group | C-DRG-00909 |
| Pediatric Exclusivity Study Basis | C-DRG-00910 |
| Pediatric Exclusivity Study Drug List | C-DRG-00911 |
| Geriatric Use Supplement Rule | C-DRG-00913 |
| Geriatric Use Supplement Clinical Efficacy Trials Category | C-DRG-00914 |
| Geriatric Use Supplement PK/PD Category | C-DRG-00915 |
| Geriatric Use Supplement Safety/Adverse Reaction Category | C-DRG-00916 |
| Industry Meeting Type | C-DRG-00917 |
| Industry Meeting Response | C-DRG-00918 |
| PACT Commitment Category | C-DRG-00919 |
| PACT Fulfillment Category | C-DRG-00920 |
| Global Suplement Status | C-DRG-00921 |
| Plant Part | C-DRG-00924 |
| SPL Coating | C-DRG-0925 |
| SPL Symbol | C-DRG-0926 |
| SPL Color | C-DRG-0927 |
| SPL Size | C-DRG-0928 |
| SPL Shape | C-DRG-0929 |
| SPL Score | C-DRG-0930 |
| SPL Imprint | C-DRG-0931 |
| SPL Image | C-DRG-0932 |
| SPL DEA Schedule | C-DRG-0933 |
| SPL Flavor | C-DRG-0934 |
| Marketing Category | C-DRG-0935 |
-
-